SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for BODY & MIND INC. (BMMJ) (CIK 0001715611) — Mar 16, 2020

BODY & MIND INC. (BMMJ) (CIK 0001715611)
Date: March 16, 2020 · CIK: 0001715611 · Accession: 0000000000-20-002336

AI Filing Summary & Sentiment

File numbers found in text: 333-237143

Date
March 16, 2020
Author
Not clearly detected
Form
UPLOAD
Company
BODY & MIND INC. (BMMJ) (CIK 0001715611)

Letter

March 16, 2020 Michael Mills President, Interim Chief Executive Officer Body & Mind Inc. 750 – 1095 West Pender Street Vancouver, BC, Canada V6E 2M6 Re:Body & Mind Inc. Registration Statement on Form S-1 Filed March 13, 2020 File No. 333-237143 Dear Mr. Mills: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Shannon - McMillan LLP

Show Raw Text
March 16, 2020
Michael Mills
President, Interim Chief Executive Officer
Body & Mind Inc.
750 – 1095 West Pender Street
Vancouver, BC, Canada V6E 2M6
Re:Body & Mind Inc.
Registration Statement on Form S-1
Filed March 13, 2020
File No. 333-237143
Dear Mr. Mills:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michael Shannon - McMillan LLP